Showing results (101-110 of 122) with videos related to
Sort By:
Pageof 13
The New England Journal of Medicine|December 9, 2014
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphomaStephen M Ansell, Alexander M Lesokhin, Ivan Borrello, et al.Cell Reports|January 24, 2019
Impaired LXRα Phosphorylation Attenuates Progression of Fatty Liver DiseaseNatalia Becares, Matthew C Gage, Maud Voisin, et al.Journal for Immunotherapy of Cancer|January 22, 2026
Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancerDung T Le, Gunnar Folprecht, Anna M Varghese, et al.The Lancet. Oncology|August 4, 2023
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 studyShubham Pant, Martin Schuler, Gopa Iyer, et al.Cancer Chemotherapy and Pharmacology|May 13, 2016
Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumorsShivaani Kummar, Alice Chen, Martin Gutierrez, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2026
A Phase 2 Trial of an Extended-release siRNA Implant Targeting KRAS G12D/V in Locally Advanced Pancreatic CancerBrinda Alagesan, Anna M Varghese, Celina Ang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2019
An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid TumorsRui Wang, Chan Gao, Megan Raymond, et al.Journal for Immunotherapy of Cancer|January 21, 2022
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter studyPaolo Andrea Zucali, Chia-Chi Lin, Bradley C Carthon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyAlexander M Lesokhin, Stephen M Ansell, Philippe Armand, et al.American Journal of Ophthalmology|June 16, 2023
Comprehensive Genotyping and Phenotyping Analysis of GUCY2D-Associated Rod- and Cone-Dominated DystrophiesCristina Rodilla, Inmaculada Martín-Merida, Fiona Blanco-Kelly, et al.Pageof 13